BridgeBio Pharma, Inc.
BBIO
$68.54
$2.593.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 14.94% | -5.54% | -0.46% | -8.65% | 36.83% |
| Total Depreciation and Amortization | -17.35% | 2.65% | 6.15% | 2.57% | -6.07% |
| Total Amortization of Deferred Charges | 25.28% | -67.84% | -- | -- | -21.50% |
| Total Other Non-Cash Items | 5.43% | 17.92% | -11.55% | -1.18% | 52.68% |
| Change in Net Operating Assets | -351.44% | 1,362.05% | -120.24% | 116.72% | -997.38% |
| Cash from Operations | -249.66% | 48.51% | -35.81% | 59.50% | -2.00% |
| Capital Expenditure | -109.09% | 92.98% | 20.88% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -197.93% | -390.25% | 139.76% | -677.93% | 50.00% |
| Cash from Investing | -197.72% | -421.55% | 134.33% | -715.17% | 50.73% |
| Total Debt Issued | -- | -- | -100.00% | -47.83% | 15.00% |
| Total Debt Repaid | -- | -- | -- | 100.00% | -- |
| Issuance of Common Stock | 112.34% | 64.74% | 12.03% | 24.33% | 102.18% |
| Repurchase of Common Stock | -1,065.20% | -145.62% | -51.63% | 96.01% | -3,464.96% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -202.47% | -35.24% | -88.57% | 72.55% | 58.65% |
| Cash from Financing | 25,301.28% | -144.07% | -100.30% | 400.66% | -87.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 524.75% | 31.18% | -150.88% | 248.30% | -151.02% |